Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study
Purpose Androgen deprivation therapy (ADT) use in prostate cancer (PCa) has seen a rising trend. We are looking into the relationship between ADT and development of metabolic diseases in Chinese patients. Methods This is a prospective multi-centre cohort yielded from the READT database (Real-life ex...
Gespeichert in:
| Veröffentlicht in: | International urology and nephrology 2022-05, Vol.54 (5), p.993-1000 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1000 |
|---|---|
| container_issue | 5 |
| container_start_page | 993 |
| container_title | International urology and nephrology |
| container_volume | 54 |
| creator | Wong, Chris Chu, Peggy Teoh, Jeremy Chiu, Peter Yee, C. H. Chau, Lysander Chan, Marco Wan, Helen Leung, Steven Ng, C. F. |
| description | Purpose
Androgen deprivation therapy (ADT) use in prostate cancer (PCa) has seen a rising trend. We are looking into the relationship between ADT and development of metabolic diseases in Chinese patients.
Methods
This is a prospective multi-centre cohort yielded from the READT database (Real-life experience of ADT in Asia), in which patients diagnosed of PCa and offered ADT were prospectively recruited since 2016. Chinese patients recruited from Hong Kong were selected and compared to another cohort of newly diagnosed PCa patients in Hong Kong (HK-Cap database), which was collected prospectively and retrieved retrospectively for this study. Patient outcomes are followed through for 2 years. We compared between the groups the new diagnoses of hypertension, diabetes and hyper-lipidaemia, as well as the initiation of related medication for these conditions. Baseline characteristics including pre-treatment comorbidities, medications and tumour characteristics are documented.
Results
151 patients receiving ADT (from READT database) and 447 patients not receiving ADT (from HK-Cap database) were analysed. ADT is related to higher risks of developing any of concerned medical co-morbidities (23.8% vs 13.0*,
p
= 0.001) and new-onset DM (16.6% vs 4.4%,
p |
| doi_str_mv | 10.1007/s11255-022-03151-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2633857592</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2633857592</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-84274e2cdc34571a3145d1bf43bfcf29eb64fe77172b3f48caf68976ea7255193</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS1UREvhBbpAlrphE_DvOOkOjfiTKiEhWFuOc91xm9ip7VSax-CNcTptQSxYWLbs75x7fQ9CZ5S8o4So95lSJmVDGGsIp5I27Bk6oVLxhslWHP11PkYvc74mhHQtIS_QMZeMqo6oE_Tru883GUeHJyimj6O3ePAZTIaMTRjWleIVBDzAnPydKT4GXHaQzLzHLiY8p5iLKYCtCRYS9gEbvN35ABnwHOdlvNdc1NsVncEWfwd4WsbiGwuhpCqNu5gKzmUZ9q_Qc2fGDK8f9lP089PHH9svzeW3z1-3Hy4by5UsTSuYEsDsYLmQihpOhRxo7wTvnXWsg34jHChFFeu5E601btN2agNG1aHRjp-itwff2tXtArnoyWcL42gCxCVrtuG8lUp2rKLn_6DXcUmhdlcp0Qm2OlaKHShbv5kTOF0HNpm015ToNTB9CEzXwPR9YHq1fvNgvfQTDE-Sx4QqwA9Ark_hCtKf2v-x_Q0IwqLw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2649422551</pqid></control><display><type>article</type><title>Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Wong, Chris ; Chu, Peggy ; Teoh, Jeremy ; Chiu, Peter ; Yee, C. H. ; Chau, Lysander ; Chan, Marco ; Wan, Helen ; Leung, Steven ; Ng, C. F.</creator><creatorcontrib>Wong, Chris ; Chu, Peggy ; Teoh, Jeremy ; Chiu, Peter ; Yee, C. H. ; Chau, Lysander ; Chan, Marco ; Wan, Helen ; Leung, Steven ; Ng, C. F.</creatorcontrib><description>Purpose
Androgen deprivation therapy (ADT) use in prostate cancer (PCa) has seen a rising trend. We are looking into the relationship between ADT and development of metabolic diseases in Chinese patients.
Methods
This is a prospective multi-centre cohort yielded from the READT database (Real-life experience of ADT in Asia), in which patients diagnosed of PCa and offered ADT were prospectively recruited since 2016. Chinese patients recruited from Hong Kong were selected and compared to another cohort of newly diagnosed PCa patients in Hong Kong (HK-Cap database), which was collected prospectively and retrieved retrospectively for this study. Patient outcomes are followed through for 2 years. We compared between the groups the new diagnoses of hypertension, diabetes and hyper-lipidaemia, as well as the initiation of related medication for these conditions. Baseline characteristics including pre-treatment comorbidities, medications and tumour characteristics are documented.
Results
151 patients receiving ADT (from READT database) and 447 patients not receiving ADT (from HK-Cap database) were analysed. ADT is related to higher risks of developing any of concerned medical co-morbidities (23.8% vs 13.0*,
p
= 0.001) and new-onset DM (16.6% vs 4.4%,
p
< 0.001). Initiation of new medications is also more common in ADT patients. New anti-hypertensives (37.8% vs 12.5%,
p
< 0.001), oral hypoglycemic agents (12.6% vs 4.9%,
p
= 0.001), insulin (4.0% vs 0.05%,
p
= 0.001) and statin (23.7% vs 12.8%,
p
= 0.023) are more commonly added in ADT cohort.
Conclusion
Chinese receiving ADT are exposed to increased risks of new-onset hypertension, diabetes and hyper-lipidaemia, and a higher likelihood of stepping up pharmaceutical control for pre-existing comorbidities. This highlights physicians’ role to monitor metabolic profiles in at-risk men upon offering ADT.</description><identifier>ISSN: 1573-2584</identifier><identifier>ISSN: 0301-1623</identifier><identifier>EISSN: 1573-2584</identifier><identifier>DOI: 10.1007/s11255-022-03151-2</identifier><identifier>PMID: 35217907</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Androgen Antagonists - adverse effects ; Androgens ; China - epidemiology ; Cohort analysis ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus - drug therapy ; Humans ; Hypertension ; Hypertension - drug therapy ; Hypertension - epidemiology ; Hypoglycemic agents ; Insulin ; Male ; Medicine ; Medicine & Public Health ; Metabolic disorders ; Nephrology ; Patients ; Prospective Studies ; Prostate cancer ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - epidemiology ; Prostatic Neoplasms - pathology ; Retrospective Studies ; Tumors ; Urology ; Urology - Original Paper</subject><ispartof>International urology and nephrology, 2022-05, Vol.54 (5), p.993-1000</ispartof><rights>The Author(s), under exclusive licence to Springer Nature B.V. 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer Nature B.V.</rights><rights>The Author(s), under exclusive licence to Springer Nature B.V. 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-84274e2cdc34571a3145d1bf43bfcf29eb64fe77172b3f48caf68976ea7255193</citedby><cites>FETCH-LOGICAL-c375t-84274e2cdc34571a3145d1bf43bfcf29eb64fe77172b3f48caf68976ea7255193</cites><orcidid>0000-0003-1795-1198</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11255-022-03151-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11255-022-03151-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35217907$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wong, Chris</creatorcontrib><creatorcontrib>Chu, Peggy</creatorcontrib><creatorcontrib>Teoh, Jeremy</creatorcontrib><creatorcontrib>Chiu, Peter</creatorcontrib><creatorcontrib>Yee, C. H.</creatorcontrib><creatorcontrib>Chau, Lysander</creatorcontrib><creatorcontrib>Chan, Marco</creatorcontrib><creatorcontrib>Wan, Helen</creatorcontrib><creatorcontrib>Leung, Steven</creatorcontrib><creatorcontrib>Ng, C. F.</creatorcontrib><title>Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study</title><title>International urology and nephrology</title><addtitle>Int Urol Nephrol</addtitle><addtitle>Int Urol Nephrol</addtitle><description>Purpose
Androgen deprivation therapy (ADT) use in prostate cancer (PCa) has seen a rising trend. We are looking into the relationship between ADT and development of metabolic diseases in Chinese patients.
Methods
This is a prospective multi-centre cohort yielded from the READT database (Real-life experience of ADT in Asia), in which patients diagnosed of PCa and offered ADT were prospectively recruited since 2016. Chinese patients recruited from Hong Kong were selected and compared to another cohort of newly diagnosed PCa patients in Hong Kong (HK-Cap database), which was collected prospectively and retrieved retrospectively for this study. Patient outcomes are followed through for 2 years. We compared between the groups the new diagnoses of hypertension, diabetes and hyper-lipidaemia, as well as the initiation of related medication for these conditions. Baseline characteristics including pre-treatment comorbidities, medications and tumour characteristics are documented.
Results
151 patients receiving ADT (from READT database) and 447 patients not receiving ADT (from HK-Cap database) were analysed. ADT is related to higher risks of developing any of concerned medical co-morbidities (23.8% vs 13.0*,
p
= 0.001) and new-onset DM (16.6% vs 4.4%,
p
< 0.001). Initiation of new medications is also more common in ADT patients. New anti-hypertensives (37.8% vs 12.5%,
p
< 0.001), oral hypoglycemic agents (12.6% vs 4.9%,
p
= 0.001), insulin (4.0% vs 0.05%,
p
= 0.001) and statin (23.7% vs 12.8%,
p
= 0.023) are more commonly added in ADT cohort.
Conclusion
Chinese receiving ADT are exposed to increased risks of new-onset hypertension, diabetes and hyper-lipidaemia, and a higher likelihood of stepping up pharmaceutical control for pre-existing comorbidities. This highlights physicians’ role to monitor metabolic profiles in at-risk men upon offering ADT.</description><subject>Androgen Antagonists - adverse effects</subject><subject>Androgens</subject><subject>China - epidemiology</subject><subject>Cohort analysis</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus - drug therapy</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - epidemiology</subject><subject>Hypoglycemic agents</subject><subject>Insulin</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic disorders</subject><subject>Nephrology</subject><subject>Patients</subject><subject>Prospective Studies</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - epidemiology</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Retrospective Studies</subject><subject>Tumors</subject><subject>Urology</subject><subject>Urology - Original Paper</subject><issn>1573-2584</issn><issn>0301-1623</issn><issn>1573-2584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kc1u1DAUhS1UREvhBbpAlrphE_DvOOkOjfiTKiEhWFuOc91xm9ip7VSax-CNcTptQSxYWLbs75x7fQ9CZ5S8o4So95lSJmVDGGsIp5I27Bk6oVLxhslWHP11PkYvc74mhHQtIS_QMZeMqo6oE_Tru883GUeHJyimj6O3ePAZTIaMTRjWleIVBDzAnPydKT4GXHaQzLzHLiY8p5iLKYCtCRYS9gEbvN35ABnwHOdlvNdc1NsVncEWfwd4WsbiGwuhpCqNu5gKzmUZ9q_Qc2fGDK8f9lP089PHH9svzeW3z1-3Hy4by5UsTSuYEsDsYLmQihpOhRxo7wTvnXWsg34jHChFFeu5E601btN2agNG1aHRjp-itwff2tXtArnoyWcL42gCxCVrtuG8lUp2rKLn_6DXcUmhdlcp0Qm2OlaKHShbv5kTOF0HNpm015ToNTB9CEzXwPR9YHq1fvNgvfQTDE-Sx4QqwA9Ark_hCtKf2v-x_Q0IwqLw</recordid><startdate>20220501</startdate><enddate>20220501</enddate><creator>Wong, Chris</creator><creator>Chu, Peggy</creator><creator>Teoh, Jeremy</creator><creator>Chiu, Peter</creator><creator>Yee, C. H.</creator><creator>Chau, Lysander</creator><creator>Chan, Marco</creator><creator>Wan, Helen</creator><creator>Leung, Steven</creator><creator>Ng, C. F.</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1795-1198</orcidid></search><sort><creationdate>20220501</creationdate><title>Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study</title><author>Wong, Chris ; Chu, Peggy ; Teoh, Jeremy ; Chiu, Peter ; Yee, C. H. ; Chau, Lysander ; Chan, Marco ; Wan, Helen ; Leung, Steven ; Ng, C. F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-84274e2cdc34571a3145d1bf43bfcf29eb64fe77172b3f48caf68976ea7255193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Androgen Antagonists - adverse effects</topic><topic>Androgens</topic><topic>China - epidemiology</topic><topic>Cohort analysis</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus - drug therapy</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - epidemiology</topic><topic>Hypoglycemic agents</topic><topic>Insulin</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic disorders</topic><topic>Nephrology</topic><topic>Patients</topic><topic>Prospective Studies</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - epidemiology</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Retrospective Studies</topic><topic>Tumors</topic><topic>Urology</topic><topic>Urology - Original Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wong, Chris</creatorcontrib><creatorcontrib>Chu, Peggy</creatorcontrib><creatorcontrib>Teoh, Jeremy</creatorcontrib><creatorcontrib>Chiu, Peter</creatorcontrib><creatorcontrib>Yee, C. H.</creatorcontrib><creatorcontrib>Chau, Lysander</creatorcontrib><creatorcontrib>Chan, Marco</creatorcontrib><creatorcontrib>Wan, Helen</creatorcontrib><creatorcontrib>Leung, Steven</creatorcontrib><creatorcontrib>Ng, C. F.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>International urology and nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wong, Chris</au><au>Chu, Peggy</au><au>Teoh, Jeremy</au><au>Chiu, Peter</au><au>Yee, C. H.</au><au>Chau, Lysander</au><au>Chan, Marco</au><au>Wan, Helen</au><au>Leung, Steven</au><au>Ng, C. F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study</atitle><jtitle>International urology and nephrology</jtitle><stitle>Int Urol Nephrol</stitle><addtitle>Int Urol Nephrol</addtitle><date>2022-05-01</date><risdate>2022</risdate><volume>54</volume><issue>5</issue><spage>993</spage><epage>1000</epage><pages>993-1000</pages><issn>1573-2584</issn><issn>0301-1623</issn><eissn>1573-2584</eissn><abstract>Purpose
Androgen deprivation therapy (ADT) use in prostate cancer (PCa) has seen a rising trend. We are looking into the relationship between ADT and development of metabolic diseases in Chinese patients.
Methods
This is a prospective multi-centre cohort yielded from the READT database (Real-life experience of ADT in Asia), in which patients diagnosed of PCa and offered ADT were prospectively recruited since 2016. Chinese patients recruited from Hong Kong were selected and compared to another cohort of newly diagnosed PCa patients in Hong Kong (HK-Cap database), which was collected prospectively and retrieved retrospectively for this study. Patient outcomes are followed through for 2 years. We compared between the groups the new diagnoses of hypertension, diabetes and hyper-lipidaemia, as well as the initiation of related medication for these conditions. Baseline characteristics including pre-treatment comorbidities, medications and tumour characteristics are documented.
Results
151 patients receiving ADT (from READT database) and 447 patients not receiving ADT (from HK-Cap database) were analysed. ADT is related to higher risks of developing any of concerned medical co-morbidities (23.8% vs 13.0*,
p
= 0.001) and new-onset DM (16.6% vs 4.4%,
p
< 0.001). Initiation of new medications is also more common in ADT patients. New anti-hypertensives (37.8% vs 12.5%,
p
< 0.001), oral hypoglycemic agents (12.6% vs 4.9%,
p
= 0.001), insulin (4.0% vs 0.05%,
p
= 0.001) and statin (23.7% vs 12.8%,
p
= 0.023) are more commonly added in ADT cohort.
Conclusion
Chinese receiving ADT are exposed to increased risks of new-onset hypertension, diabetes and hyper-lipidaemia, and a higher likelihood of stepping up pharmaceutical control for pre-existing comorbidities. This highlights physicians’ role to monitor metabolic profiles in at-risk men upon offering ADT.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>35217907</pmid><doi>10.1007/s11255-022-03151-2</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-1795-1198</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1573-2584 |
| ispartof | International urology and nephrology, 2022-05, Vol.54 (5), p.993-1000 |
| issn | 1573-2584 0301-1623 1573-2584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2633857592 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Androgen Antagonists - adverse effects Androgens China - epidemiology Cohort analysis Diabetes Diabetes mellitus Diabetes Mellitus - drug therapy Humans Hypertension Hypertension - drug therapy Hypertension - epidemiology Hypoglycemic agents Insulin Male Medicine Medicine & Public Health Metabolic disorders Nephrology Patients Prospective Studies Prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - epidemiology Prostatic Neoplasms - pathology Retrospective Studies Tumors Urology Urology - Original Paper |
| title | Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T02%3A16%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risks%20of%20metabolic%20diseases%20and%20androgen%20deprivation%20therapy%20for%20prostate%20cancer%20in%20a%20Chinese%20population:%20a%20prospective%20multi-centre%20cohort%20study&rft.jtitle=International%20urology%20and%20nephrology&rft.au=Wong,%20Chris&rft.date=2022-05-01&rft.volume=54&rft.issue=5&rft.spage=993&rft.epage=1000&rft.pages=993-1000&rft.issn=1573-2584&rft.eissn=1573-2584&rft_id=info:doi/10.1007/s11255-022-03151-2&rft_dat=%3Cproquest_cross%3E2633857592%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2649422551&rft_id=info:pmid/35217907&rfr_iscdi=true |